FDA 483 - Biomat USA Inc - March 07, 2019

An FDA inspection of Bio-Blood Components Inc in Columbus, OH, a source plasma establishment, revealed two significant observations. These included inadequate preparation of phlebotomy sites, leading to concerns about sterility, and a failure to timely submit multiple biological product deviation reports. These issues indicate potential non-compliance with regulations concerning donor safety and reporting requirements.